Cryoablation for Advanced and Refractory Desmoid Tumors

Recruiting

• Conditions: Desmoid Tumors

• Registration Number: NCT06113094
• Lead Sponsor: University Hospital, Strasbourg, France

Brief Summary

Desmoid tumors, also called aggressive fibromatosis, are rare, locally invasive tumors with no potential for metastasis. The incidence is approximately 2 to 4 per million per year in the general population. The "watch and wait" policy is the standard of care for newly diagnosed patients in Europe. Patients who progress have first-line medical treatment, surgery is no longer the treatment because there is a high rate of recurrence (\> 60%) and radiotherapy is not very suitable because the patients are often young and the tumors are large. Cryoablation seems to be an effective therapeutic option that should be evaluated.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-07-07
• Status Verified: 2022-11
• Study First Submitted: 2022-11-14
• Study First Submitted QC: 2023-10-30
• Last Update Submitted: 2023-10-30
• Study First Posted: 2023-11-02
• Last Update Posted: 2023-11-02
• Primary Completion: 2023-12
• Study Completion: 2023-12-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Progression-free survival assessed using RECIST(Response evaluation criteria in solid tumors) criteria	at 6 months after cryoablation

Trial Locations

Locations (1)

Service d'Imagerie Interventionnelle - CHU de Strasbourg - France; 🇫🇷 Strasbourg, France